DRUG
Bright MindsยทNASDAQ
--
--(--)
--
--(--)
DRUG Profile
Bright Minds Biosciences Inc.
A biotech company focused on developing novel drugs for the targeted treatment of neuropsychiatric disorders, epilepsy, and pain
Biological Technology
05/31/2019
11/08/2021
NASDAQ Stock Exchange
25
09-30
Common stock
400 N Aberdeen St Suite 900
Chicago
IL 60642
--
Bright Minds Biosciences Inc., was incorporated on May 31, 2019 under the British Columbia Business Companies Act. The company is a biotechnology company that develops innovative therapies to improve the lives of people with severe and life-changing neurological and psychiatric disorders. The Bright Minds pipeline includes novel compounds targeting key receptors in the brain to address diseases with high unmet medical needs, including epilepsy, depression and other central nervous system (CNS) diseases. The company focuses on delivering breakthrough therapies that transform patients' lives. The company has developed a unique highly selective serotonergic agonist platform that exhibits selectivity on different serotonergic receptors. This provides a rich portfolio of Novel Chemical Entities (NCE) projects in the fields of Neurology and Psychiatry.
